Nexus Biopharma, Inc. (NEXS) financial statements (2021 and earlier)

Company profile

Business Address JLABS @ TMCX
HOUSTON, TX 77021-2040
State of Incorp.
Fiscal Year End February 28
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

2/28/2017
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0   0
Cash and cash equivalents0   0
Prepaid expense1 5 
Total current assets:1 5 0
Noncurrent Assets
Property, plant and equipment2    
Intangible assets, net (including goodwill)7  
Intangible assets, net (excluding goodwill)7    
Total noncurrent assets:8    
TOTAL ASSETS:10 5 0
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:83626162210
Accounts payable20026162210
Other undisclosed accounts payable and accrued liabilities636    
Debt293    
Due to related parties8859   
Other undisclosed current liabilities200 322117
Total current liabilities:1,41685494227
Noncurrent Liabilities
Long-term debt and lease obligation48    
Long-term debt, excluding current maturities48    
Total noncurrent liabilities:48    
Total liabilities:1,46385494227
Stockholders' equity
Stockholders' equity attributable to parent, including:(1,454)(85)(44)(42)(27)
Common stock64    
Additional paid in capital1,776424242(86)
Accumulated deficit(3,294)(191)(149)(148)(133)
Other undisclosed stockholders' equity attributable to parent 646464191
Total stockholders' equity:(1,454)(85)(44)(42)(27)
TOTAL LIABILITIES AND EQUITY:10 5 0

Income statement (P&L) ($ in thousands)

2/28/2017
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Gross profit:(30)    
Operating expenses(655)(42)(3)(31)(33)
Operating loss:(685)(42)(3)(31)(33)
Interest and debt expense (27)   
Net loss:(685)(69)(3)(31)(33)
Other undisclosed net income (loss) attributable to parent(1)2711523
Net loss available to common stockholders, diluted:(686)(42)(1)(15)(9)

Comprehensive Income ($ in thousands)

2/28/2017
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(685)(69)(3)(31)(33)
Comprehensive loss, net of tax, attributable to parent:(685)(69)(3)(31)(33)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: